anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
* Patients should be counseled that antibacterial drugs including Meropenem for Injection and Sodium Chloride Injection should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Meropenem for Injection and Sodium Chloride Injection is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Meropenem for Injection and Sodium Chloride Injection or other antibacterial drugs in the future. 
  * Counsel patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial drug is discontinued. Sometimes after starting treatment with antibacterial drugs, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial drug. If this occurs, patients should contact their physician as soon as possible [see Warnings and Precautions (5.5)]. 
  * Counsel patients to inform their physician if they are taking valproic acid or divalproex sodium. Valproic acid concentrations in the blood may drop below the therapeutic range upon co-administration with Meropenem for Injection and Sodium Chloride Injection. If treatment with Meropenem for Injection and Sodium Chloride Injection is necessary and continued, alternative or supplemental anti-convulsant medication to prevent and/or treat seizures may be needed [see Warnings and Precautions (5.4)]. 
  * Patients receiving Meropenem for Injection and Sodium Chloride Injection on an outpatient basis must be alerted of adverse events such as seizures, delirium, headaches and/or paresthesias that could interfere with mental alertness and/or cause motor impairment. Until it is reasonably well established that Meropenem for Injection and Sodium Chloride Injection is well tolerated, patients should not operate machinery or motorized vehicles [see Warnings and Precautions (5.9)].
  * Meropenem for Injection and Sodium Chloride Injection contains a high sodium load. Instruct patients to inform or report symptoms of difficulty breathing, swelling, or increased weight [see Warnings and Precautions (5.10)].
Ethyl chloride spray (Cryogesic®, Fannin Ltd, Dublin, Ireland). Applied topically to surgical site prior to LA injection. Spray at distance of 5-10cm for 4-8 seconds until skin slightly blanched and the fluid allowed to evaporate.
Guided by the theory of dyadic illness management, this study examined the association between the within-couple incongruence regarding perceptions of pain experienced by adults with fibromyalgia (AwFM) and symptoms of depression and anxiety in AwFM and their partners. Participants included 204 couples. Three second-order dyadic variables were created from the couples' perceptions of pain interference experienced by AwFM: (1) absolute magnitude of incongruence in perception of pain, (2) average perception of pain, and (3) direction of incongruence (i.e., who perceives pain to be higher). Structural equational modeling was used to examine the association between the three dyadic variables and AwFM and partner symptoms of depression and anxiety, adjusting for covariates. These steps were repeated for pain severity. Higher average perception of pain interference within the couple was associated with greater symptoms of depression and anxiety in AwFM and partners. AwFM exhibited greater symptoms of depression when their perception of their pain interference was higher than their partner's. Incongruence variables were not significantly associated with AwFM or partners' anxiety symptoms. Near identical results were found for pain severity. A dyadic approach to mental health treatment, which includes enhanced communication skills, should be adopted to optimize the mental health of couples living with fibromyalgia.
The invention contains a water soluble block copolymer and a reverse thermo-sensitivity reversible aquogel composite including at least one correlation gel adjuvant. The water soluble block copolymer contains at least two polyethylene oxide blocks and a polypropylene oxide block. The solubility of the correlation gel adjuvant in water is less than 0.5g/100ml and a better choice is less than 0.3g/100ml. The correlation gel adjuvant is able to form water soluble intermolecular complex with water soluble block copolymer. The aquogel composite shows improved gel efficiency and improvement for solubility and/or stability of slightly water soluble and/or water insoluble reagent. The aquogel composite can be applied to various medicine and cosmetic products, such as treatment for esophagus, ear, vagina, rectum, eye and skin diseases and defects.
Patients receive acalabrutinib PO BID on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive acalabrutinib PO BID on days 1-84. Treatment repeats every 84 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients may continue treatment with acalabrutinib If MRD negative CR/CRi is not achieved after 12 cycles.
The invention belongs to the field of pharmaceutical chemical synthesis, and particularly relates to a synthesis method of a metal carbene photodiagnosis and treatment agent. The metal carbene photodiagnosis and treatment agent has a structure shown as a formula (I) or a formula (II); formula (I); formula (II); wherein X is H, cl, br or Ome, M is Ag, au or Cu, Y is Cl, br or I, R is alkyl with 1-12 carbon atoms, 、 Or (b) . The introduction of the N-heterocyclic carbene in the metal carbene photodiagnosis and treatment agent shortens the distance between two molecules of perylene imide, enhances the intramolecular interaction, strengthens the interstitial crossing and intramolecular charge transfer, leads to the improvement of non-radiative relaxation, and finally greatly improves the photo-thermal and photodynamic performances of the obtained photodiagnosis and treatment agent. The method has the characteristics of stable and simple process, high yield, good stability and the like. The photodiagnosis and treatment agents with different electronic properties and light conversion properties can be obtained by simply replacing the N-heterocyclic carbene type. The synthesis method has the characteristics of good universality, easy separation of products, high yield and the like.
Yale is the central site for this multicenter study. Patients with HCM and LQTS will be recruited via high-volume HCM and LQTS sites, patient-groups, and websites. Information about exercise participation will be acquired via interview and online instruments at enrollment and every six months for three years. Quality of Life questionnaires will be filled out at enrollment and at the end of the study. Participants will receive a Fitbit (pedometer) and will wear it initially for two weeks and then one week every three months. The Fitbit is used for assessment of exercise level only. Clinical records will be obtained from treating physicians. Participants will also be asked to call the central site if they experience syncope, appropriate ICD (implantable cardioverter defibrillator) shock, or resuscitated arrest. Information regarding the patient's activity at the time of event will then be obtained by phone interview. Follow-up clinical records will be obtained as indicated to corroborate endpoints.

The Ancillary study is optional. This will include all of the baseline questionnaires,as well as selected questions from the Epi-Pandemic Impacts Inventory.
In the present invention, we solve the problem of facilitating blood pool measurements accessible to patients or researchers by using 18FDG for the in vitro intracellular labeling of RBCs (Red blood cells). 18FDG tracer is available worldwide and as a glucose analogue it may be incorporated by the erythrocytes and trapped intracellularly. In this sense, a blood sample (such as whole peripheral blood) can be extracted or isolated from a subject or from another subject with blood compatibility. The extracted or isolated blood can be then incubated in contact with 18FDG for a period of time and later be reinjected into the patient. Labeling of RBCs with 18FDG will expand the use of the PET technique to blood pool imaging with the consequent improvement in the field of clinical diagnosis. l
The present invention relates to a preparation with traditional Chinese medicine as raw materials for treating hepatopathy. The present invention solves the problems of the existing medicine of one-sided treatment, inconspicuous curative effect, long course of treatment and high expense. The present invention is composed of 18 kinds of traditional Chinese medicine such as pangolin scale, turtle shell, leech, ground beetle, red sage root, safflower, astragalus root, dried tangerine peel, rhizome, poria from yunnan of china, notoginseng, red ginseng, etc. through processes of pulverizing, sieving, rolling, etc. according to traditional Chinese medicine integral viewpoints. The present invention has the main functions of supporting healthy energy and activating blood circulation to dissipate blood stasis, has the auxiliary functions of dispersing the stagnated liver qi for relieving qi stagnation, fortifying the spleen, harmonizing the stomach, nourishing the liver and the kidney, restoring qi, detoxifying, resolving phlegm and promoting urination, and is suitable for being used for treating the hepatopathy such as hepatitis B, chronic active hepatitis, hepatitis B chronic persistent hepatitis, liver cirrhosis splenomegaly, early liver cancer, benign liver tumor, etc.
Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) is the most common type of hematologic malignancy in the pediatric population (ages 0-19). Despite favorable prognosis in pediatric B-ALL as a whole, outcomes remain poor for patients who have relapsed or are refractory (R/R) to standard therapies. The Federal and Drug Administration (FDA) approved CD19-directed chimeric antigen receptor T-cell therapy (CAR T cell) based on an 80+% remission induction rate thus expanding treatment options for this subtype of leukemia. However, despite the high remission rates induced by CD19-directed CAR T cell therapy, the current FDA-approved chimeric antigen receptor therapies (CARs) have limitations associated with the durability of response. Additionally, relapse due to loss of the targeted antigen (CD19 negative) is a frequent cause of resistance to CD19-targeted cell therapy. This study will investigate a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22). This CAR T cell therapy can be used in patients with CD19-negative relapse after initial CD19-targeted cell therapy or in naive CAR T cell patients with the goal of reducing CD19-negative relapses.
The increasing prevalence of people with Parkinson's disease (PD) necessitates a high priority for finding interventions to delay or even prevent the onset of PD. There is converging evidence that exercise may exert disease-modifying effects in people with clinically manifest PD, but whether exercise also has a preventive effect or is able to modify the progression of the pathology in the prodromal phase of PD is unclear. Here we provide some considerations on the design of trials that aim to prevent PD through exercise. First, we discuss the who could benefit from exercise, and potential exercise-related risks. Second, we discuss what specific components of exercise mediate the putative disease-modifying effects. Third, we address how methodological challenges such as blinding, adherence and remote monitoring could be handled and how we can measure the efficacy of exercise as modifier of the course of prodromal PD. We hope that these considerations help in designing exercise prevention trials for persons at risk of developing PD.
This paper, in a nutshell, is a plea for community participation in research along with an adapted idea for how such participation should be shaped and understood. I will give varied examples of the ways in which scientists viewing a perceived problem solely from an external perspective has led to mistakes. If we do not properly take into account the knowledge and values of people with a condition, we are liable to pursue the wrong sorts of treatments. In particular, I provide examples of three ways (exemplified in the cases of "female hysteria", autism, and chronic fatigue syndrome) scientists are liable to pursue treatment of what they perceive to be at least partially mental illnesses that they/we shouldn't. I present the idea of deliberative research-the concept is based on that of deliberative democracy. The idea of deliberative democracy is that decisions should be made on the basis of reasons that would be acceptable to the target population. I similarly argue that research decisions should be made on the basis of reasons that would be acceptable to the target population, even if it requires other experts to determine how those reasons are best to be respected in the context of a particular project.
BACKGROUND: Diarrhea is a leading cause of death in young children worldwide. Vitamin D deficiency impairs the body's ability to clear pathogens, reduces tight junction protein expression in intestinal epithelial cells, and enhances Th1-mediated intestinal inflammation. This study aimed to investigate the effects of serum vitamin D levels on acute invasive enteritis in children.
METHODS: This prospective cohort study included 82 children aged 1-3 years with clinically diagnosed acute invasive enteritis at Sichuan Maternal and Child Health Hospital from February 2021 to February 2022, alongside a control group of 80 healthy children. Fecal specimens were collected for routine tests and occult blood analysis, while blood samples were taken for routine tests, C-reactive protein, and 25-OHD levels. Comparative analyses were performed between groups, and multifactorial logistic regression was used to identify factors influencing invasive enteritis.
RESULTS: The study group showed significantly lower serum 25-OHD levels (27.95 ± 9.91 ng/mL) compared to controls (32.76 ± 10.23 ng/mL, p < .01). Among the study group, 19.5% (16/82) had levels <20 ng/mL, versus 12.5% (10/80) in controls. Regular vitamin D supplementation was lower in the study group (58.5% vs. 77.5%, p < .05). Outdoor activity duration was also reduced (2.57 ± 0.98 h vs. 3.04 ± 0.88 h, p < .01). Multivariate analysis identified that exclusive breastfeeding, greater outdoor activity time and regular vitamin D supplementation were all associated with reduced risk of invasive enteritis (p < .05).
CONCLUSION: The findings indicate an association between low serum 25-OHD levels and acute invasive enteritis in children aged 1-3 years, suggesting that consistent vitamin D supplementation and sufficient outdoor activity may protect against this condition.
The effectiveness of the immediate-release formulation of ropinirole (REQUIP Tablets) in the treatment of early and advanced Parkinson’s disease was initially established in 3 randomized, double-blind, placebo-controlled trials.

The effectiveness of REQUIP XL in the treatment of Parkinson’s disease was supported by 2 randomized, double-blind, multicenter clinical trials and clinical pharmacokinetic considerations. One trial conducted in advanced Parkinson’s disease patients compared REQUIP XL with placebo as adjunctive therapy to L-dopa. A second trial compared REQUIP XL with REQUIP Tablets in early phase Parkinson’s disease patients not receiving L-dopa.

In these studies a variety of measures were used to assess the effects of treatment (e.g., patient diaries recording time “on” and “off,” tolerability of L-dopa dose reductions, and the Unified Parkinson’s Disease Rating Scale [UPDRS] scores). The UPDRS is a multi-item rating scale evaluating mentation (Part I), activities of daily living (Part II), motor performance (Part III), and complications of therapy (Part IV). Part III of the UPDRS contains 14 items designed to assess the severity of the cardinal motor findings in patients with Parkinson’s disease (e.g., tremor, rigidity, bradykinesia, postural instability, etc.) scored for different body regions and has a maximum (worst) score of 108.
FIELD: medicine. SUBSTANCE: method involves giving to patient Phenazepam tablet and hypnosis session is administered. The patient is set into resource comfort state and programmed for living sober. The session being over, 20-40 drops of 1: 10 diluted ethanol solution and Carbamazepin tablet are given to the patient during 4-10 days. Phenazepam tablet of 0.001 g is sublingually administered to the patient. The hypnosis session is carried out during 45 min on the background of coniferous needles, lilac, seawater odor. 96 °  ethanol is diluted in 1:10 proportion in Hypericum L. infusion. Diluted ethanol and Carbamazepin tablet the patient takes before supper 30 min before meals. EFFECT: enhanced effectiveness of treatment. 5 cl
PURPOSE: To obtain a new readily usable inhibitor of glucosyltransferases, containing an essential oil of a plant body and having high safety and a cleaning agent for the oral cavity and a food and drink having preventing actions on carious teeth imparted thereto by adding the inhibitor thereto. CONSTITUTION: This inhibitor of glucosyltransferases contains about 0.001-5wt.% an essential oil obtained by carrying out the steam distillation of a plant body selected from the pericarp of an orange, a leaf of a eucalyptus or a mugwort and a flower of a lavender or a rose as an active ingredient (the essential oil of the eucalyptus is blended in a dentifrice, etc.) and prepared into a formulation by further suitably blending optional adjuvants, excipients, water or organic solvents, etc., therewith. The resultant formulation is capable of inhibiting activities of glucosyltransferases which are enzymes capable of synthesizing glucan causing dental caries and effective in prevention of the dental caries.  The inhibitor can be added to a cleaning agent for the oral cavity to use its inhibiting actions on the glucosyltransferases for preventing the glucan from being produced in the oral cavity. The inhibitor can be added to a food and drink containing sucrose for preventing the glucan from being produced and the dental caries from causing.
The category of ALK -rearranged mesenchymal neoplasms has been evolving rapidly, with reports of morphologically diverse lesions of cutaneous, soft tissue, and visceral origin. While some of these represent morphologically defined entities harboring recurrent ALK fusions (inflammatory myofibroblastic tumor and epithelioid fibrous histiocytoma), others are unclassified by morphology with variable overlap with the tyrosine kinase family of neoplasia and their underlying ALK fusions cannot be suspected based on morphology. We herein report 3 cases that expand the anatomic, morphologic, and genotypic spectrum of ALK -rearranged unclassified neoplasms. Patients were all adults aged 46 to 69 (median: 63) who presented with a mass located in the gingiva, subcutis of the back, and submucosal posterior pharyngeal wall. The tumor size ranged from 1 to 2.7 cm (median: 1.6). Conservative surgery was the treatment in all patients. Follow-up was available for one patient who remained disease-free at 14 months. Histologically, all tumors displayed large polygonal cells with foamy to granular and lipogenic-like microvacuolated copious cytoplasm and medium-sized round nuclei with 1 or 2 prominent nucleoli. Mitoses and necrosis were not seen. The initial diagnostic impression was PEComa, inflammatory rhabdomyoblastic tumor and unclassified pseudolipogenic neoplasm. Strong cytoplasmic ALK was detected by immunohistochemistry in all cases. Other positive markers include Cathepsin K (2/2), desmin (1/3), focal MyoD1 (1/1), focal SMA (1/3), and focal EMA (1/2). Targeted RNA sequencing revealed ALK fusions with exon 20 (2 cases) and exon 19 (one case) of ALK fused to RND3 (exon 3), SQSTM1 (exon 6), and desmin (intron 6). Methylation profiling in the desmin-fused case (initially diagnosed as inflammatory rhabdomyoblastic tumor) revealed an inflammatory myofibroblastic tumor match with a low confidence score of 0.5 and a flat copy number variation (CNV) profile. No NF1 mutation was detected in this case, altogether excluding an inflammatory rhabdomyoblastic tumor. Our study highlights and expands the morphologic and anatomic diversity of ALK- fused neoplasms and documents novel fusion partners ( RND3 and desmin).
In Part 1 participants received 50 mg cinacalcet capsules orally once a day (QD) for 6 weeks. In Part 2 participants received 30 mg cinacalcet capsules twice a day for 15 days.
Patients who were initially randomized to Stelara group on Day 1 (Week 0) will be randomized again in a ratio of 1:1 to either continue Stelara or undergo transition to CT-P43 prior to dosing at Week 16. Thereafter, patients will continue their treatment until Week 40.
The present invention provides novel peptides. These peptides are useful as renin inhibitors and have a novel cyclic tripeptide of formula (I) at the N-terminus. Some of these peptides also have a non-cleavable transition state insert corresponding to the 10,11-position of the renin substrate (angiotensinogen). Renin inhibitors are useful for the diagnosis and control of renin-dependent hypertension, congestive heart failure, renin-dependent hyperaldosterism, other renin-dependent cardiovascular disorders and ocular disorders. These peptides are also useful as inhibitors of HIV-I protease. Inhibitors of HIV-I protease are useful for treating humain acquired immunodeficiency disease syndrome (AIDS).
PROBLEM TO BE SOLVED: To provide an improved filming compsn for animal skin prophylactic and protective agent which forms an elastic film when it is applied on the skin and improves binding properties and durability of the film while ease of use and preventive protective ability which polyether polyurethane/benzoin gum compsn. has are kept. SOLUTION: A filming compsn. for skin prophylactic and protective agent which contains a film-formable ingredient dispersed in a carrier and can form an elastic film when the skin is coated with it, is provided. In this case, nitrocellulose dispersed in the carrier by such an amt. that can increase enough the time for which the compsn. sticks on the skin in comparison with a compsn. being the same except no nitrocellulose is incorporated, is incorporated.
This paper analyzes rural-urban disparities in life expectancy with and without pain among upper-middle age and older adults. Data are from the nationally representative Health and Retirement Study, 2000-2018, N = 18,160, age 53+. Interpolated Markov Chain software, based on the multistate life tables, is used to calculate absolute and relative pain expectancies by age, sex, rural-suburban-urban residence and U.S. regions. Results show significant rural disadvantages versus those in urban and often suburban areas. Example: males at 55 in rural areas can expect to live 15.1 years, or 65.2 percent pain-free life, while those in suburban areas expect to live 1.7 more years, or 2.6 percentage points more, pain-free life and urban residents expect to live 2.4 more year, or 4.7 percentage points more. The rural disadvantage persists for females, with differences being a little less prominent. At very old age (85+), rural-urban differences diminish or reverse. Rural-urban pain disparities are most pronounced in the Northeast and South regions, and least in the Midwest and West. The findings highlight that rural-urban is an important dimension shaping the geography of pain. More research is needed to disentangle the mechanisms through which residential environments impact people's pain experiences.